Shengnuo Biotechnology IPO: industrialization transformation of several first class peptide drugs
- Recently, Chengdu Shengnuo Biotechnology Co., Ltd. (hereinafter referred to as “Shengnuo Biotechnology”) is applying for listing on the A-share sci tech innovation board.
- Shengnuo Biotechnology mainly develops and produces raw materials and peptide drug preparations, which are used in autoimmune diseases, HIV-1 infected patients, etc.
Recently, Chengdu Shengnuo Biotechnology Co., Ltd. (hereinafter referred to as “Shengnuo Biotechnology”) is applying for listing on the A-share sci tech innovation board.
It plans to issue no more than 20 million shares, accounting for no less than 25% of the share capital after the issuance. The sponsor is Minsheng Securities Co., Ltd.
Founded in 2001, Shengnuo Biotechnology is a first-class international enterprise specializing in large-scale production of peptide and amino acid drugs.
At present, it has a number of key technologies for large-scale production of peptides that have been listed at home and abroad. The zero defect has passed the FDA certification of the United States.
It has undertaken the key research projects of National Eleventh Five Year Plan major new drug creation, and has successively won the titles of “National high-tech enterprise”, “Sichuan enterprise technology center” and “Chengdu polypeptide drug engineering technology research center”.
Shengnuo Biotechnology mainly develops and produces raw materials and peptide drug preparations, which are used in autoimmune diseases, HIV-1 infected patients, etc.
in addition, the company also provides professional peptide drug research and development services, undertaking peptide projects at home and abroad, especially cro of innovative polypeptide projects/ At present, C (d) Mo business has the annual production of polypeptide raw materials above tons, solid preparations of more than 400 million tablets (granules), freeze-dried powder injection, small volume injection, pre filled injection, cartridge injection batch production.
In the early stage, multinational enterprises such as Novartis Pharmaceutical Co., Ltd., syrano Co., Ltd. and other foreign brand peptide drugs have entered China, and all of them have achieved market success.
However, at present, China’s polypeptide drug industry is still in its infancy and growth stage. As the industry leader, Sinochem actively cooperates with domestic enterprises.
At present, it has successfully realized the industrialization transformation of multiple class I peptide new drugs for Chengdu Dior, Zhejiang Haizheng, Harbin Pharmaceutical Group, Hainan Zhonghe and frontier Biology (Nanjing).
Shengnuo Biotechnology’s wholly-owned subsidiary has also realized commercial production. Several polypeptide API production workshops have passed the official GMP certification of China, the United States, South Korea and Mexico.